Partner Content Partner Content Less than 4 Weeks until Immuno-Therapy Experts Gather at the... Less than 4 Weeks until Immuno-Oncology Conference
News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
